A Novel Strategy for Targeting Castrate-Resistant Prostate Cancer

Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology

R Quezada Urban, S Keerthikumar, A Clark, H Wang, B Phipson, A Bakshi, A Ryan, H Thorne, RA Taylor, MG Lawrence, GP Risbridger, R Toivanen, DL Goode

2025-10-01

Neuroendocrine prostate cancer (NEPC) tumours are classified by pathology into several distinct subtypes. Gene expression profilin..

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants

MG Lawrence, S Keerthikumar, SL Townley, AK Clark, GB Cuffe, G Laven-Law, AR Hanson, RK Shrestha, TP Knutson, MG Richards, L Teng, N Choo, M Crumbaker, AM Joshua, E Corey, PS Nelson, SM Dehm, GP Risbridger, WD Tilley, TE Hickey

2025-09-01

Background and objective: Under the selective pressure of treatment, prostate cancer cells express constitutively active androgen ..

Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer

N Choo, S Keerthikumar, S Ramm, D Ashikari, L Teng, B Niranjan, S Hedwards, LH Porter, DL Goode, KJ Simpson, RA Taylor, GP Risbridger, MG Lawrence

2024-06-01

There are diverse phenotypes of castration-resistant prostate cancer, including neuroendocrine disease, that vary in their sensiti..

Defining the challenges and opportunities for using patient-derived models in prostate cancer research

W Nathaniel Brennen, Clementine Le Magnen, Sofia Karkampouna, Nicolas Anselmino, Nathalie Bock, Nicholas Choo, Ashlee K Clark, Ilsa M Coleman, Robin Dolgos, Alison M Ferguson, David L Goode, Marianna Krutihof-de Julio, Nora M Navone, Peter S Nelson, Edward O'Neill, Laura H Porter, Weranja Ranasinghe, Takuro Sunada, Elizabeth D Williams, Lisa M Butler

2024-05-01

Background: There are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes tra..

The future of patient-derived xenografts in prostate cancer research

MG Lawrence, RA Taylor, GB Cuffe, LS Ang, AK Clark, DL Goode, LH Porter, C Le Magnen, NM Navone, JA Schalken, Y Wang, WM van Weerden, E Corey, JT Isaacs, PS Nelson, GP Risbridger

2023-06-01

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to st..

OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer

D Obinata, D Funakoshi, K Takayama, M Hara, B Niranjan, L Teng, MG Lawrence, RA Taylor, GP Risbridger, Y Suzuki, S Takahashi, S Inoue

2022-12-01

Androgen and androgen receptor (AR) targeted therapies are the main treatment for most prostate cancer (PC) patients. Although AR ..

Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer

M Alizadeh-Ghodsi, KL Owen, SL Townley, D Zanker, SPG Rollin, AR Hanson, R Shrestha, J Toubia, T Gargett, I Chernukhin, J Luu, KJ Cowley, A Clark, JS Carroll, KJ Simpson, JM Winter, MG Lawrence, LM Butler, GP Risbridger, B Thierry

2022-07-01

Inhibiting the androgen receptor (AR), a ligand-activated transcription Increased ERV expression led to accumulation of double-str..

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

GP Risbridger, AK Clark, LH Porter, R Toivanen, A Bakshi, NL Lister, D Pook, CJ Pezaro, S Sandhu, S Keerthikumar, R Quezada Urban, M Papargiris, J Kraska, HB Madsen, H Wang, MG Richards, B Niranjan, S O’Dea, L Teng, W Wheelahan

2021-12-01

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-d..

CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition

MG Lawrence, LH Porter, N Choo, D Pook, JP Grummet, CJ Pezaro, S Sandhu, S Ramm, J Luu, A Bakshi, DL Goode, E Sanij, RB Pearson, RD Hannan, KJ Simpson, RA Taylor, GP Risbridger, L Furic

2021-11-01

Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologo..

High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids

N Choo, S Ramm, J Luu, JM Winter, LA Selth, AR Dwyer, M Frydenberg, J Grummet, S Sandhu, TE Hickey, WD Tilley, RA Taylor, GP Risbridger, MG Lawrence, KJ Simpson

2021-10-01

New treatments are required for advanced prostate cancer; however, there are fewer preclinical models of prostate cancer than othe..

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer

LH Porter, A Bakshi, D Pook, A Clark, D Clouston, J Kourambas, DL Goode, GP Risbridger, RA Taylor, MG Lawrence

2021-06-01

Amplifications of the androgen receptor (AR) occur in up to 80% of men with castration-resistant prostate cancer (CRPC). Recent st..

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer

RC Fernandes, J Toubia, S Townley, AR Hanson, BK Dredge, KA Pillman, AG Bert, JM Winter, R Iggo, R Das, D Obinata, S Sandhu, GP Risbridger, RA Taylor, MG Lawrence, LM Butler, A Zoubeidi, PA Gregory, WD Tilley, TE Hickey

2021-01-05

Neuroendocrine prostate cancer is an aggressive disease subtype associated with poor patient outcome. Fernandes et al. demonstrate..

PDX: Moving beyond drug screening to versatile models for research discovery

GP Risbridger, MG Lawrence, RA Taylor

2020-11-01

Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all disciplines and medical specialties. Most e..

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer

D Obinata, MG Lawrence, K Takayama, N Choo, GP Risbridger, S Takahashi, S Inoue

2020-10-08

The androgen receptor (AR) is the main therapeutic target in advanced prostate cancer, because it regulates the growth and progres..

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer

LH Porter, MG Lawrence, H Wang, AK Clark, A Bakshi, D Obinata, D Goode, M Papargiris, null Mural, D Clouston, A Ryan, S Norden, E Corey, PS Nelson, JT Isaacs, J Grummet, J Kourambas, S Sandhu, DG Murphy, D Pook

2019-08-01

Background: Serially transplantable patient-derived xenografts (PDXs) are invaluable preclinical models for studying tumor biology..

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, N Lister, D Pook, CJ Pezaro, DL Goode, RJ Rebello, AK Clark, M Papargiris, J Van Gramberg, AR Hanson, P Banks, H Wang, B Niranjan, S Keerthikumar, S Hedwards

2018-11-01

Background: The intractability of castration-resistant prostate cancer (CRPC) is exacerbated by tumour heterogeneity, including di..